Patents Assigned to LipoLytics Therapeutics, LLC
  • Thyroid-stimulating hormone receptor polypeptide agonist glycoforms to treat metabolic syndrome
    Patent number: 9333241
    Abstract: TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: May 10, 2016
    Assignee: LipoLytics Therapeutics, LLC
    Inventor: James D. Kelly